Peakadilly appoints Nick McCooke as CEO
EUR 6 million first close of Series A financing
Peakadilly NV announced that it has completed the first close of a Series A financing raising EUR 6 million. The transaction was led by Life Science Partners (LSP) and co-led by Johnson & Johnson Development Corporation (JJDC). Peakadilly also announced the appointments to the board of directors of Nick McCooke as CEO, and Martijn Kleijwegt and Zeev Zehavi as non-executive directors representing LSP and JJDC respectively.
The new proceeds will be used to increase the capacity of Peakadilly's protein biomarker discovery operation based on its proprietary MASStermind(TM) technology, enabling it to expand its relationships with pharma and diagnostic companies and to accelerate development of its own diagnostic and pharmacodiagnostic products. Coincident with the funding, Peakadilly founder, VIB (Flanders Interuniversity Institute of Biotechnology), completed the contribution in kind to Peakadilly of the core technology underpinning MASStermind.
Nick McCooke, who joins the company as CEO, brings considerable experience in the start-up and growth of biotech and pharma services businesses in Europe, the USA and Japan. As the first CEO of Solexa, he took the ultra-throughput DNA sequencing company from university spinout to its reverse takeover of a US based company and resulting NASDAQ listing. He takes over from founding CEO, Koen Kas, who becomes CSO.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
